Replies to post #79 on Nektar Therapeutics (NKTR)

[surf1944]

Sweet on Nektar Therapeutics
The biopharmaceutical firm is seeing much activity for its NKTR-102 drug.

Nektar Therapeutics (NKTR: Nasdaq) By Boenning & Scattergood ($9.95, May 16, 2011)

We are initiating coverage of Nektar Therapeutics with an Outperform rating and a target price of $15.

Based on the remarkable activity of Nektar's (ticker: NKTR) drug called NKTR-102 (made of polymer conjugated irinotecan) in advanced ovarian (platinum resistant and refractory) and breast cancers (taxane and anthracycline failures), we are not surprised that management has retained control of ...

http://online.barrons.com/article/SB50001424052970204038504576329714169261514.html?ru=yahoo&mod=yahoobarrons